NBE Therapeutics in the News

Select a year

December 17 - Chemical & Engineering News: Boehringer Ingelheim to acquire ADC firm NBE-Therapeutics

Read more

December 11 - Pharmaceutical Business Review: Boehringer to acquire Swiss biotech company NBE-Therapeutics for €1.18bn

Read more

December 10 - BioCentury: More enthusiasm for ADCs as Boehringer buys NBE, gaining conjugate platform

Read more

December 10 - MedNous: Boehringer to acquire NBE-Therapeutics

Read more

December 10 - Fierce Biotech: Biotech Boehringer inks $1.5B NBE buyout, joining Merck in new cancer race

Read more

December 10 - ThePharmaLetter: Another immune-oncology acquisition for Boehringer

Read more

December 10 - Pharmaceutical Technology: Boehringer to acquire NBE-Therapeutics for $1.43bn

Read more

December 10 - Endpoints News: Boehringer Ingelheim buys out next-gen ADC player NBE-Therapeutics in a deal worth up to $1.4B+

Read more

December 10 - S&P Global: UPDATE: Boehringer Ingelheim to buy cancer-focused NBE-Therapeutics for €1.18B

Read more

December 10 - BioWorld: Boehringer Ingelheim to pay up to $1.4B for ADC developer NBE-Therapeutics

Read more

December 10 - pharmaphorum: Boehringer buys NBE for €1.18bn, adding cancer ADC expertise

Read more

December 10 - Evaluate Vantage: Ror1 delivers its second takeout in five weeks

Read more

December 10 - SCRIP Intelligence: Boehringer Buys Antibody-Drug Conjugates Biotech NBE For €1.18bn

Read more

September 17 - BioProcess International: Exelixis: Deals with NBE and Catalent bring multi-pronged ADC approach

Read more

September 9 - Pharmaceutical Business Review: Exelixis, NBE join forces for discovery and development of ADCs for cancer

Read more

September 8 - ThePharmaLetter: Exelixis and NBE-Therapeutics to work together

Read more

September 8 - pharmaphorum: Exelixis doubles down on ADCs for cancer with NBE, Catalent deals

Read more